- 2019 American Journal of obstetrics. AJOG. Important study regarding M281, a monoclonal anti-FcRn antibody. If the study eventually shows blocking of FcRn with Nipocalimab is a safe and effective way to manage HDFN, the same strategy could be applied to FNAIT. This once a week treatment was well tolerated in a Phase 1 study in ...
1 June 2020. FNAIT progess update from: James B Bussel, MD. Pediatric Hematology & Oncology New York, NY Dear Members of NAITBABIES and the community interested in Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): It gives me great pleasure to tell you about the progress that has been and is being made in regard to FNAIT. ...- Rallybio have announced the following news regarding financing, development and it’s Lead Product Candidate, RLY211. RLYB211 is a plasma-derived hyperimmune globulin in development for the prevention of FNAIT. Press release 19 May 2020 Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020 ...
Due to the pandemic coronavirus – COVID-19 Naitbabies have postponed future exhibitions and conferences until further notice. We are working from home and our online Parents Support Group is still very much active. Please find links below to Government and WHO websites. and information for pregnant women and COVID-19 UK Royal College Obstetricians ...
We ‘re excited to be exhibiting at The first All Ireland Maternity and Midwifery Festival Croke Park, Dublin February 11 2020
Cambridge Rare Disease Network are hosting #RAREsummit19 which takes place on 23rd September at the Wellcome Genome Campus, Hinxton, Cambridgeshire, England. #RAREsummit19 is a 1 day event focusing on patient-centricity in rare disease progress; highlighting exemplars of patient, patient advocacy groups and carers involvement in the development of drugs, healthcare and assistive technologies. Taking place ...
